Welcome to our dedicated page for Eyepoint Pharmac SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EyePoint Pharmaceuticals’ SEC filings are packed with dense ophthalmology data—think multi-phase trial outcomes, sustained-release chemistry, and milestone royalty clauses. Finding the R&D burn rate or the status of DURAVYU™ in a 300-page 10-K is challenging.
Stock Titan solves this problem. Our AI-powered summaries turn every EyePoint Pharmaceuticals SEC filing into plain English, so you can move from jargon to judgment in minutes. Whether you’re tracking an 8-K material event for trial readouts, skimming a quarterly earnings report 10-Q filing for cash runway, or reviewing proxy statement executive compensation, we deliver the context that matters.
You’ll find every form, updated in real time as they hit EDGAR:
- EyePoint Pharmaceuticals insider trading Form 4 transactions with instant alerts
- EyePoint Pharmaceuticals annual report 10-K simplified—AI highlights pivotal pipeline risks
- EyePoint Pharmaceuticals Form 4 insider transactions real-time, revealing executive sentiment
- EyePoint Pharmaceuticals earnings report filing analysis that pinpoints R&D spend trends
- EyePoint Pharmaceuticals 8-K material events explained in clear language
Use our platform to:
- Spot executive stock transactions before catalysts
- Compare quarter-over-quarter clinical expense trajectories
- Understand licensing revenue streams without combing footnotes
Stop wrestling with complex biotechnology disclosures. Start understanding EyePoint Pharmaceuticals SEC documents with AI—all in one place, always current.
EyePoint Pharmaceuticals (EYPT) Chief Financial Officer George Elston reported transfers of company common stock on September 19, 2025. The filing shows 20,000 shares were disposed of from Mr. Elston's direct holdings and the same number were recorded as held indirectly in an irrevocable family trust for the benefit of his children, with JP Morgan Trust Company of Delaware as trustee. After the reported transactions, Mr. Elston's direct beneficial ownership is reported as 62,114 shares and the Family Trust holds 20,000 shares. The filing also notes 1,266 shares were acquired on July 31, 2025 under EyePoint’s 2019 Employee Stock Purchase Plan. The reporting attorney-in-fact signed the form on September 22, 2025.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 6,800,000 shares of EyePoint Pharmaceuticals common stock, representing 9.88% of the company based on 68,811,736 shares outstanding. The filing states the reporting persons hold shared voting and shared dispositive power over the shares and report no sole voting or dispositive power. Adage is identified as the investment manager of the entity that directly holds the shares. The reporting persons certify these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Form 8-K/A overview: This amendment only fixes a broken hyperlink in the original 8-K filed 29 Jul 2025. The substance of the report is unchanged.
Material event (Item 8.01): EyePoint Pharmaceuticals (EYPT) has completed enrollment in its pivotal Phase 3 clinical trials of DURAVYU™ for wet age-related macular degeneration (wet AMD). Completion of enrollment marks the final operational step before data collection and analysis.
- Press release detailing the milestone is furnished as Exhibit 99.1.
- An updated investor presentation is furnished as Exhibit 99.2.
No financial results, guidance, or other transactions are disclosed. The filing signals continued pipeline progress but investors must await trial read-out for efficacy and safety outcomes.
Schedule 13G/A (Amendment 1) filed for EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) discloses that Federated Hermes, Inc. and related reporting persons—Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue—collectively hold 4,599,450 shares of EyePoint common stock, representing 6.68 % of the outstanding class as of 30 June 2025.
The filing is made under Rule 13d-1(b) indicating a passive investment. Federated Hermes has sole voting and dispositive power over all reported shares; the individual Donahues share voting/dispositive power through the Trust. No other parties share control, and the group certifies the stake was acquired in the ordinary course of business with no intent to influence control of the issuer.
Key details for investors:
- Ownership threshold: Stake exceeds the 5 % reporting trigger, signalling meaningful institutional involvement.
- Aggregation structure: Shares are held via a Pennsylvania-based trust controlled by Federated Hermes executives, consolidating voting power.
- Certification: Reporting persons affirm the investment is non-activist and purely passive.
No financial performance data, purchase price or transaction timing beyond the “Date of Event” are provided.
FAQ
What is the current stock price of Eyepoint Pharmac (EYPT)?
What is the market cap of Eyepoint Pharmac (EYPT)?
